Last reviewed 2026-05-22 · How we verify

EMEPRONIUM

Phase 2 active Small molecule

EMEPRONIUM is a emepronium drug. It is currently in Phase 2 development.

Emepronium works by blocking certain ion channels in the body.

Emepronium is a small molecule drug in the emepronium class, but its target and approved indications are unknown. Its bioavailability is low at 1%. The commercial status of eMepronium is unclear, and it is not known if it is patented or available as a generic. Further information on its pharmacokinetics, such as half-life, is also unavailable. As a result, key safety considerations and FDA approval status are also unknown.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	EMEPRONIUM
Drug class	emepronium
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Imagine your body's cells have special doors that let certain things in and out. Emepronium is like a key that blocks some of these doors, which can help treat certain conditions. This can affect how your body responds to stimuli and can help with symptoms.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

EMEPRONIUM CI brief — competitive landscape report
EMEPRONIUM updates RSS · CI watch RSS

Frequently asked questions about EMEPRONIUM

What is EMEPRONIUM?

EMEPRONIUM is a emepronium drug.

How does EMEPRONIUM work?

Emepronium works by blocking certain ion channels in the body.

What drug class is EMEPRONIUM in?

EMEPRONIUM belongs to the emepronium class. See all emepronium drugs at /class/emepronium.

What development phase is EMEPRONIUM in?

EMEPRONIUM is in Phase 2.

Drug class: All emepronium drugs
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing